Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | MET | P08581 | 10/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | AXL | P30530 | 4/20 | 0.46 |
| ▸ | MERTK | Q12866 | 4/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SPHK1 | Q9NYA1 | 3/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | RET | P07949 | 1/20 | 0.46 |
| ▸ | KIT | P10721 | 1/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL2458178 | 0.98 | ALDH1A1 (0.55) | ALDH1A1METLMNASMN1; SMN2AXL | |
| Hydrochloric Acid SCHEMBL29453838 | 0.98 | ALDH1A1 (0.55) | ALDH1A1METLMNASMN1; SMN2AXL | |
| SCHEMBL3856060 | 0.93 | ALDH1A1 (0.53) | ALDH1A1METLMNASMN1; SMN2AXL | |
| Cadaverine Tartrate SCHEMBL29678843 | 0.90 | ALDH1A1 (0.46) | ALDH1A1METLMNASMN1; SMN2AXL | |
| SCHEMBL12468984 | 0.89 | ALDH1A1 (0.53) | ALDH1A1METAXLMERTKGAA | |
| SCHEMBL21299310 | 0.88 | ALDH1A1 (0.55) | ALDH1A1METLMNASMN1; SMN2AXL | |
| SCHEMBL411823 | 0.85 | ALDH1A1 (0.51) | ALDH1A1METLMNASMN1; SMN2AXL | |
| SCHEMBL19026688 | 0.85 | MET (0.51) | ALDH1A1METAXLMERTKGAA | |
| SCHEMBL18256972 | 0.85 | MET (0.54) | ALDH1A1METAXLMERTKGAA | |
| SCHEMBL105644 | 0.84 | ALDH1A1 (0.48) | ALDH1A1METAXLMERTKGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 188 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114040912-B | Compounds for the treatment of kinase dependent disorders | 埃克塞里艾克西斯公司 | 2024-10-25 | — | — | CN | claimed |
| CN-117919242-A | Antitumor pharmaceutical composition | 南昌弘益药业有限公司 | 2024-04-26 | — | — | CN | claimed |
| CN-116963734-A | Crystalline salts of multiple tyrosine kinase inhibitors, process for their preparation and their use | 米拉蒂治疗股份有限公司 | 2023-10-27 | — | — | CN | claimed |
| WO-2023193563-A1 | CRYSTAL FORM A OF THIENOPYRIDINE COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL COMPOSITION THEREOF | 深圳海王医药科技研究院有限公司 | 2023-10-12 | — | — | WO | claimed |
| WO-2023155777-A1 | N- [ (6-BROMOPYRIDIN-3-YL) METHYL] -2-METHOXYETHAN-1-AMINE SALTS AND PREPARATION THEREOF | BEIGENE (SUZHOU) CO., LTD. (CN) | 2023-08-24 | — | — | WO | claimed |
| US-11673897-B2 | Compounds for the treatment of kinase-dependent disorders | EXELIXIS, INC. (US) | 2023-06-13 | — | — | US | claimed |
| US-20230167063-A1 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer | EXELIXIS, INC. | 2023-06-01 | — | — | US | claimed |
| WO-2023056202-A2 | COMPOSITIONS AND METHODS FOR ENHANCED PROTEIN PRODUCTION | HDT BIO CORP. (US) | 2023-04-06 | — | — | WO | claimed |
| CN-110386901-B | Compound containing sulfonanilide pyrimidine structure and application thereof as antitumor drug | 上海医药工业研究院 | 2022-11-25 | — | — | CN | claimed |
| WO-2022169248-A1 | NOVEL COMPOUND AS PROTEIN KINASE INHIBITOR | 주식회사 엘지화학 | 2022-08-11 | — | — | WO | claimed |
| EP-3329918-B1 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2022-05-25 | — | — | EP | claimed |
| CN-114401720-A | Crystal form of polytyrosine kinase inhibitor, preparation method and application thereof | 米拉蒂治疗股份有限公司 | 2022-04-26 | — | — | CN | claimed |
| CN-114040912-A | Compounds for the treatment of kinase-dependent disorders | 埃克塞里艾克西斯公司 | 2022-02-11 | — | — | CN | claimed |
| US-20210040076-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | EXELIXIS, INC. | 2021-02-11 | — | — | US | claimed |
| CN-105153028-B | Compound as c-Met kinase inhibitor | 南京爱德程医药科技有限公司 | 2019-03-26 | — | — | CN | claimed |
| CN-105683191-B | Protein kinase inhibitor containing pyrrolopyridazine derivative | 井标记生物 | 2019-03-26 | — | — | CN | claimed |
| WO-2009077874-A2 | A PHARMACEUTICAL COMPOSITION FOR TREATING ESOPHAGEAL CANCER | EISAI R & D MANAGEMENT CO., LTD. (US) | 2009-06-25 | — | — | WO | claimed |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | claimed |
| US-12503438-B2 | Compounds for the treatment of kinase-dependent disorders | EXELIXIS, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| US-20070054928-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167063-A1 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer | MDH1, MDH2, SLC25A11 | ALDH1A1 819/4885MET 266/4885LMNA 3940/4885 |
| US-20070054928-A1 | c-Met modulators and methods of use | FLT4, FLT1, MET | ALDH1A1 2072/4885MET 3/4885LMNA 2924/4885 |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | HGF, MET, FLT1 | ALDH1A1 1649/4885MET 2/4885LMNA 4411/4885 |
| US-20210040076-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | ERBB2, MAP3K6, MAP3K1 | ALDH1A1 3310/4885MET 154/4885LMNA 2013/4885 |
| US-12503438-B2 | Compounds for the treatment of kinase-dependent disorders | ERBB2, ERBB3, PTK2B | ALDH1A1 3579/4885MET 105/4885LMNA 2516/4885 |
| US-11673897-B2 | Compounds for the treatment of kinase-dependent disorders | ERBB2, MAP3K6, PRKCH | ALDH1A1 3263/4885MET 117/4885LMNA 1522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.